Trials / Completed
CompletedNCT04828265
Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
A Phase 1, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Aldafermin in Healthy Adult Male Japanese and Non-Japanese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label study to assess safety, tolerability, and pharmacokinetics of Aldafermin (NGM282) in healthy adult male Japanese and non-Japanese subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Aldafermin | Single dose of aldafermin |
Timeline
- Start date
- 2021-04-13
- Primary completion
- 2021-07-06
- Completion
- 2021-07-06
- First posted
- 2021-04-02
- Last updated
- 2022-01-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04828265. Inclusion in this directory is not an endorsement.